Fourth Wave of Opioid (Illicit Drug) Epidemic: Cause and Effect Relationship

Laxmaiah Manchikanti, MD

Laxmaiah Manchikanti, MD

Chairman of the Board, and Chief Executive Officer: ASIPP, and SIPMS

Co-Founder & Director: Pain Management Centers of America

Medical Director: Pain Management Centers of Paducah and Marion, ASC, PCS

Clinical Professor

Anesthesiology and Perioperative Medicine University of Louisville, KY

Professor of Anesthesiology-Research

Department of Anesthesiology, School of Medicine LSU Health Sciences Center New Orleans and Shreveport, LA

Board Certified: ABA, ABA Pain Medicine, ABIPP

Member: Kentucky CAC

Served on KASPER-Drug Abuse Task Force, KY, Board of Regents,

2

Murray State University, KY; KBML; MCAC; AMA delegate

Publications: Over 550 articles and 12 books

Editorial Peer Review: 25 journals

OPIOID EPIDEMIC

The CDC declared overdoses from prescription painkillers an epidemic in 2011.

♦ Epidemic:

• Affecting or tending to affect a disproportionally large number of individuals within a population, community or region at the same time.

♦ Crisis:

- A time of intense difficulty, trouble, or danger.
- A time when a difficult or important decision must be made

♦ Endemic:

• A disease or condition regularly found among particular people or certain area.

Opioid Epidemic

U.S. with 4.8% of World's Population

- Consumes 80% of world's opioid supply
- Consumes 99% of world's hydrocodone supply
- Consumes over 80% of the world's oxycodone supply

Escalating

- Abuse
- Doctor shopping
- Deaths
- Illicit Drugs
- Inability to monitor
- High dose, multiple opioids
- Combinations (holy trinity)



Energy & Commerce Committee October 8,2004

Opioid Epidemic

U.S. with 4.4% of World's Population

- Consumes over 70% of world's opioid supply
- Consumes almost 100% of world's hydrocodone supply
- Consumes over 70% of the world's oxycodone supply

Escalating

- Deaths
- o Heroin
- Fentanyl
- Declining prescriptions




Committee Continues Efforts to Prevent Opioid Epidemic from Harming More Americans

February 6, 2018

IS IT PRESCRIPTION OPIOID EPIDEMIC OR ILLICIT DRUG EPIDEMIC


Description of fourth wave clarifies:

- ♦ It is not:
 - Opioid epidemic
 - Opioid overdose crisis
- ♦ But, it is:
 - Illicit drug epidemic
 - Illicit drug overdose crisis
 - Illicit opioid epidemic
 - Illicit opioid overdose crisis



Source: National Vital Statistics System Mortality File.

Three waves of the rise in opioid overdose deaths.



Redrawn and modified from CDC figure

Drug Overdose Deaths in the U.S. Top 100,000 Annually

- Provisional data from CDC's
 - An estimated 100,306 drug overdose deaths in the United States during 12month period ending in April 2021
 - An increase of 28.5% from the 78,056 deaths during the same period the year before.
- ◆ The new data documents that estimated overdose deaths from opioids increased to 75,673 in the 12-month period ending in April 2021, up from 56,064 the year before.
- Overdose deaths from synthetic opioids (primarily fentanyl) and psychostimulants such as methamphetamine also increased in the 12-month period ending in April 2021.
 - Cocaine deaths also increased, as did deaths from natural and semisynthetic opioids (such as prescription pain medication).

Health Services Research

Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect


Laxmaiah Manchikanti, MD¹, Vanila Mathur Singh, MD², Peter S. Staats, MD³, Andrea M. Trescot, MD⁴.5, John Prunskis, MD⁴.6,7, Nebojsa Nick Knezevic, MD, PhD®, Amol Soin, MD³.10, Alan D. Kaye, MD, PhD¹¹, Sairam Atluri, MD¹², Mark V. Boswell, MD, PhD¹³, Alaa Abd-Elsayed, MD¹⁴, and Joshua A. Hirsch, MD¹⁵

FOURTH WAVE: CAUSES (Illicit Drug Epidemic)

Confluence of multiple factors


- ♦ Increasing demand with reduced access to opioids
 - CDC guidelines
 - Application and misapplication
 - Converted into regulations
 - Regulatory atmosphere tragic failure of systems
 - COVID-19 Pandemic
 - Policies of interventional techniques
- ♦ Increased availability of illicit drugs
 - Border policies
 - Cartels

Prescription opioids abuse is least of all problems




Redrawn and modified from CDC figure

Opioid prescriptions are declining while opioid overdose deaths are increasing




Source: https://www.cdc.gov/nchs/products/databriefs/db428.htm
https://www.cdc.gov/drugoverdose/rxrate-maps/index.html
<a href="https://www.cdc



Prescription opioid use in morphine milligram equivalents (MME) per capita, 1992-2020*.

Source: IQVIA Xponent, Mar 2020; IQVIA Prescription Audit; IQVIA Institute, Nov 2020

Figure 5. Use of prescription opioids and nonopioid prescription pain medications (without prescription opioids) in the past 30 days among adults aged 20 and over: United States, 2009–2010 through 2017–2018




¹Significant linear trend.

NOTES: Prescription opioid use was defined as using one or more prescription opioids with or without nonopioid prescription pain medications. Use of nonopioid prescription pain medications (without prescription opioids) was defined as using one or more nonopioid prescription pain medications without any use of prescription opioids. Access data table for Figure 5 at: https://www.cdc.gov/nchs/data/databriefs/db369-tables-508.pdf#5.
SOURCE: NCHS, National Health and Nutrition Examination Survey, 2009–2018.

Significant difference between 2015–2016 and 2017–2018.


Fourth Wave

- ➤ In 2020, the age-adjusted rate of drug overdose deaths in the United States was 31% higher than the rate in 2019.
 - In 2020, 91,799 drug overdose deaths occurred in the United States for an ageadjusted rate of 28.3 per 100,000 standard population. The rate in 2020 (28.3) was 31% higher than the rate in 2019 (21.6)



Fourth Wave


- Since 2016, rates of drug overdose deaths involving opioids have been highest for deaths involving synthetic opioids other than methadone.
 - From 2019 to 2020, the rate increased 56%, from 11.4 to 17.8 per 100,000.
 - The age-adjusted rate of drug overdose deaths involving heroin was increased from 2005 to 2016, and decreased from 2016 through 2020.
 - The drug overdose deaths involving natural and semisynthetic opioids, changed from 2017 (4.4), rates decreased in 2018 (3.8) and 2019 (3.6) but increased in 2020 (4.0).



Hedegaard H, Miniño AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999–2020. NCHS Data Brief, no 428. Hyattsville, MD: National Center for Health Statistics. 2021.

Fourth Wave

- The rise in the age-adjusted rates of drug overdose deaths involving cocaine and psychostimulants with abuse potential that began in 2012 continued through 2020.
 - The rate of drug overdose deaths involving cocaine increased 22% in 2020 compared 2019
 - The rate of drug overdose deaths involving psychostimulants with abuse potential increase 50% in 2020 compared 2019.



Number of National Drug Overdose Deaths Involving Select Prescription and Illicit Drugs

														_
		2000	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	
İ	Total Overdose Deaths	17,415	38,329	41,340	41,502	43,982	47,055	52,404	63,632	70,237	67,367	70,630	91,799	l
ı	Any Opioid ¹	8,407	21,089	22,784	23,166	25,052	28,647	33,091	42,249	47,600	46,802	49,860	68,630	l
	Any opioid and Synthetic Opioids other than Methadone	205	1,002	961	944	1,219	2,493	4,806	9,299	12,556	13,491	13,596	16,465	
	Prescription Opioids ²	3,785	14,583	15,140	14,240	14,145	14,838	15,281	17,087	17,029	14,975	14,139	16,416	
	Prescription Opioids AND Synthetic Opioids other than Methadone	167	939	889	861	1,015	1,489	2,263	4,055	5,444	5,417	5,876	8,626	
	Prescription Opioids WITHOUT Synthetic Opioids other than Methadone	3,618	13,644	14,251	13,379	13,130	13,349	13,018	13,032	11,585	9,558	8,263	7,790	
	Synthetic Opioids other than Methadone (primarily fentanyl) ³	782	3,007	2,666	2,628	3,105	5,544	9,580	19,413	28,466	31,335	36,359	56,516	
	Heroin ⁴	1,842	3,036	4,397	5,925	8,257	10,574	12,989	15,469	15,482	14,996	14,019	13,165	١
ĺ	Cocaine ⁵	3,544	4,183	4,681	4,404	4,944	5,415	6,784	10,375	13,942	14,666	15,883	19,447	
	Psychostimulants With Abuse Potential (primarily methamphetamine) ⁶	578	1,854	2,266	2,635	3,627	4,298	5,716	7,542	10,333	12,676	16,167	23,837	
İ	Benzodiazepines ⁷	1,298	6,497	6,872	6,524	6,973	7,945	8,791	10,684	11,537	10,724	9,711	12,290	
	Antidepressants ⁸	1,798	3,889	4,113	4,259	4,458	4,768	4,894	4,812	5,269	5,064	5,175	5,597	

Source: https://nida.nih.gov/drug-topics/trends-statistics/overdose-death-rates. Accessed on 2/7/2022

[^]See https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm for technical information.

¹ Any Opioid ICD-10 codes (T40.0-T40.4, T40.6)

² Prescription Opioids ICD-10 codes (T40.2-T40.3)


⁴Heroin ICD-10 codes (T40.1)

⁵Cocaine ICD-10 codes (T40.5)

⁷Benzodiazepines ICD-10 code(T42.4)


⁸Antidepressants ICD-10 code(T43.0-T43.2)

Quantification of Opioid Deaths 2000-2020




							Change			
	2000	2010	2017	2018	2019	2020	2000- 2020	2000- 2010	2010- 2020	2019- 2020
Prescription Opioids (natural & semi-synthetic opioids & methadone)	3,785	14,583	17,029	14,975	14,139	16,416	334%	285%	13%	16%
Synthetic Opioids other than Methadone (primarily fentanyl)	782	3,007	28,466	31,335	36,359	56,516	7127%	285%	1779%	55%
Heroin	1,842	3,036	15,482	14,996	14,019	13,165	615%	65%	334%	-6%
Cocaine	3,544	4,183	13,942	14,666	15,883	19,447	449%	18%	365%	22%
Psychostimulants	578	1,854	10,333	12,676	16,167	23,837	4024%	221%	1186%	47%
Benzodiazepines	1,298	6,497	11,537	10,724	9,711	12,290	847%	401%	89%	27%

National Drug-Involved Overdose Deaths*, Number Among All Ages, 1999-2020



^{*}Includes deaths with underlying causes of unintentional drug poisoning (X40–X44), suicide drug poisoning (X60–X64), homicide drug poisoning (X85), or drug poisoning of undetermined intent (Y10–Y14), as coded in the International Classification of Diseases, 10th Revision. Source: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2020 on CDC WONDER Online Database, released 12/2021.


Effect of CDC Guidelines




A total of 109 223 patients and 139 941 person-years of follow-up are included in the analyses. Monthly outcome counts during follow-up were modeled as a function of the maximum monthly rate of dose reduction during any previous 60-day period. Thus, the less than 10% category may include patient periods prior to tapering, patients with gradual dose reductions, or patients with no dose change. Of the total cohort of 113 618 patients, 4395 (3.9%) were not included in these analyses due to an absence of follow-up time beyond the initial 60-day period or a dose increase of greater than or equal to 15% relative

to baseline in the first 60 days. Plotted estimates are adjusted for patient age, sex, education, rurality of home address, commercial vs Medicare Advantage insurance, baseline opioid dose, co-prescription of benzodiazepines, study year, number of overdose events in the baseline period, baseline depression or anxiety, alcohol use disorder, drug use disorder, psychosis, and 24 other noncancer comorbidities included in the Elixhauser comorbidity index. Error bars show 95% CIs.

Adjusted event rates for overdose and mental health crisis events related to opioid tapering




Predicted rate of one or more opioid prescription fills among commercially insured nonelderly US adults with selected noncancer pain with and without the Centers for Disease Control and Prevention guideline (observed versus counterfactual), by cohort, 2014-2018.




US adults who reported using or misusing prescription opioids in the past 12 months.


Interventional Techniques



Comparative analysis of annual US population growth, Medicare participation and utilization of interventional pain management services from 2000-2020




Comparative analysis of IPM Procedures (geometric mean)




Distribution of procedural characteristics (Rates) by type of procedures from 2000 to 2020

Impact of COVID on procedural and overall patient volume



Source: The impact of COVID-19 on interventional pain management practices is significant and long-lasting: an interventional pain management physician survey



Total cost of facets, epidurals, SCS and vertebral augmentation procedures.



Laxmaiah Manchikanti, MD

Phone: (270) 554-8373 ext 101

Phone (ASIPP): (270) 554-9412

E-mail: drm@asipp.org

https://www.linkedin.com/in/laxmaiahmanchikanti

https://www.linkedin.com/company/american-society-of-interventional-pain-pain-physicians https://www.linkedin.com/company/sipms